BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23

• Press Releases

  VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

  October 7, 2026

   · 

  4 min read
• Press Releases

  Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development

  October 7, 2026

   · 

  5 min read
• Press Releases

  AltruBio to Present Data from ALTB-268 Phase 2a Trial on Ulcerative Colitis at United European Gastroenterology (UEG) Week 2026

  October 7, 2026

   · 

  2 min read
• Press Releases

  Atsena Presents Positive Preliminary Safety and Efficacy Results from Parts A and B of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis

  October 7, 2026

   · 

  9 min read
• Press Releases

  Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants - October 7, 2026

  October 7, 2026

   · 

  6 min read
• Press Releases

  Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson’s Disease

  October 7, 2026

   · 

  7 min read
• Press Releases

  Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

  October 7, 2026

   · 

  1 min read
• Press Releases

  Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

  October 7, 2026

   · 

  7 min read
• Press Releases

  CraniUS Therapeutics Secures Second FDA 510(k) Clearance in Six Weeks and Earns U.S. Patent for NeuroPASS™ 3 Cranial Drug Delivery System

  October 7, 2026

   · 

  6 min read
• Press Releases

  Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

  October 7, 2026

   · 

  3 min read